Seeking Alpha

Progenics reports narrower-than-expected loss

  • Progenics Pharmaceuticals (PGNX) turns in a narrower-than-expected loss, but revenue comes up short of consensus.
  • Q3 Relistor net sales (as reported by Salix): $4.8M. Net sales were off 39% from Q2, but gross sales were essentially flat sequentially.
  • Q3 R&D spend: $8.1M (flat Y/Y). (PR)
  • CC at 8:30 am ET
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)